Nauman Ali made a spectacular debut with five wickets and fellow spinner Yasir Shah grabbed four to give Pakistan a seven-wicket victory in the first Test against South Africa in Karachi on Friday.
Nauman, making his Test bow at the age of 34, finished with 5-35 and Yasir took 4-79 as South Africa slumped to 245 all out in their second innings on the fourth day on a wearing National Stadium pitch that favoured spin bowlers.
Pakistan, needing 88 for victory, lost openers Abid Ali, Imran Butt and Babar Azam for a total of 52 runs before achieving the target in 22.5 overs to take a 1-0 lead in the two-match series.
The second Test starts on February 4 in Rawalpindi.
Azhar Ali was 31 not out while Fawad Alam -- who hit a fighting hundred in the first innings -- hit the winning boundary.
It was only Pakistan's fifth victory against South Africa in 27 Tests.
Anrich Nortje bowled Abid in the first over after lunch and then had Butt caught behind to finish with figures of 2-24.
Azam, on his Test captaincy debut, was dismissed leg before by Keshav Maharaj.
"The credit goes to the players," said Azam. "Our bowling was outstanding on a slow pitch and the way Yasir and Nauman bowled, it helped us get wickets.
"When we lost four early wickets Fawad and Azhar put on a good partnership as they showed their experience. It gave us a boost and a very crucial lead."
Azam's counterpart Quinton de Kock, who endured a miserable 50th Test of his career, rued South Africa's first innings collapse.
"I think our first innings cost us the game," said de Kock. "That was a big reason for our loss."
It is South Africa's first tour of Pakistan in 14 years, after a deadly attack on Sri Lanka's team in 2009 halted visits by foreign sides.
De Kock dismissed suggestions that South Africa took too long to adjust to the conditions.
"We practised enough here but I think we were a bit soft in the first innings," he said.
- Rapid conclusion -
In a spinners' battle on a brownish wicket, Nauman recorded figures of 7-73 and Yasir 7-133. In contrast, South Africa's spin bowlers managed just four wickets.
Pakistan had taken a crucial 158-run first innings lead thanks to a fighting century from Fawad and half centuries from Faheem Ashraf and Azhar.
The writing was on the wall as South Africa lost nightwatchman Maharaj on the first ball of the day, bowled for two by pacer Hasan Ali.
De Kock followed his 15 in the first innings with just two runs as he was caught off a lazy push off Yasir.
Temba Bavuma, who scored 40, added 42 for the seventh wicket with George Linde before being the last man out as Nauman took the last four wickets in a rapid 22 balls.
Having earlier removed Aiden Markram, who was caught by Abid Ali, Nauman dismissed Linde for 11, Kagiso Rabada for a single run, and Anrich Nortje for a duck, before trapping Bavuma lbw.
His impressive performance made him just the 12th Pakistani bowler to take five wickets in an innings on his debut.
UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.
Investment gap
Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.
Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.
Richard Torbett, ABPI Chief Executive, noted “The UK can lead globally in medicines and vaccines, unlocking billions in R&D investment and improving patient access but only if barriers are removed and innovation rewarded.”
The UK invests just 9% of healthcare spending in medicines, compared with 17% in Spain, and only 37% of new medicines are made fully available for their licensed indications, compared to 90% in Germany.
Expert reviews
Shailesh Solanki, executive editor of Pharmacy Business, pointed that “The government’s own review shows the sector is underfunded by about £2 billion per year. To make transformation a reality, this gap must be closed with clear plans for investment in people, premises and technology.”
The National Institute for Health and Care Excellence (NICE) cost-effectiveness threshold £20,000 to £30,000 per Quality-Adjusted Life Year (QALY) — has remained unchanged for over two decades, delaying or deterring new medicine launches. Raising it is viewed as vital to attracting foreign investment, expanding patient access, and maintaining the UK’s global standing in life sciences.
Guy Oliver, General Manager for Bristol Myers Squibb UK and Ireland, noted that " the current VPAG rate is leaving UK patients behind other countries, forcing cuts to NHS partnerships, clinical trials, and workforce despite government growth ambitions".
Reeves’ push for reform, supported by the ABPI’s Competitiveness Framework, underlines Britain’s intent to stay a leading hub for pharmaceutical innovation while ensuring NHS patients will gain faster access to new treatments.
By clicking the 'Subscribe’, you agree to receive our newsletter, marketing communications and industry
partners/sponsors sharing promotional product information via email and print communication from Garavi Gujarat
Publications Ltd and subsidiaries. You have the right to withdraw your consent at any time by clicking the
unsubscribe link in our emails. We will use your email address to personalize our communications and send you
relevant offers. Your data will be stored up to 30 days after unsubscribing.
Contact us at data@amg.biz to see how we manage and store your data.